Dinara K. Mukaneyeva

Dinara K. Mukaneyeva

Auto-generated profile, based on publicly available information

Dinara K. Mukaneyeva

National Medical Research Center for Therapy and Preventive Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
AKAnna V. Kontsevaya
Anna V. Kontsevaya
DMDinara K. Mukaneyeva
Dinara K. Mukaneyeva
YBYulia Balanova
Yulia Balanova
MKMikhail B. Khudyakov
Mikhail B. Khudyakov
ODOksana M. Drapkina
Oksana M. Drapkina
МХМ. Б. Худяков
М. Б. Худяков
The aim of this study was to evaluate economic burden of respiratory diseases and chronic obstructive pulmonary disease (COPD) in Russian Federation (RF) in 2016 including direct costs and economic losses caused by decreased labor efficiency. Methods. The analysis included direct cost, such as healthcare expenses and disablement payout, and economic losses due to decreased labor efficiency by the reason of morbidity and premature mortality. Data of Federal State Statistics Service, annual State Statistical Reports, the State Guarantee Program of Free Medical Care for Citizens of Russian Federation, and statistical data on respiratory diseases and COPD were used. Costs of medical care (ambulatory, hospital, and emergency care) were calculated based on compulsory health insurance tariffs. The amount of disability benefits payments was calculated based on number of disabled persons in each group and the size of the disability benefit. Indirect costs (or economic losses) included losses from non-produced products due to premature mortality and disability of working-aged adults. Results. In 2016, there were 623,000 years of potential life lost (YPLL) due to respiratory diseases, mainly in males. Of this, 35% of deaths and 22% of YPLL were related to COPD. Healthcare costs for COPD treatment included hospital care costs (83.9%), ambulatory care costs (11.1%) and emergency care costs (5%). In 2016, the economic burden of COPD in Russian Federation reached 170.3 billion ₽, or 18.8% of all losses and expenditures from respiratory diseases. This is 0.2% of the gross domestic product (GDP) in the same year. Conclusion. The economic burden of COPD in Russia in 2016 was 170.3 billion ₽, or 0.2% of GDP. The burden of COPD predominantly consisted of economic losses caused by premature mortality of working-aged subjects. These data suggest that priority should be given to measures aimed at preventing the occurrence and slowing down the progression of this disease, probably by increase the investment in the prevention and treatment of COPD. Such measures could reduce clinical and economic consequences of COPD.

15 August 2022 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
AKA. V. Kontsevaya
A. V. Kontsevaya
DMD. K. Mukaneeva
D. K. Mukaneeva
MSM. I. Smirnova
M. I. Smirnova
AAA. A. Antsiferova
A. A. Antsiferova
SASergey Avdeev
Sergey Avdeev
Chronic obstructive pulmonary disease (COPD) is characterized by a high level of morbidity and mortality and is associated with significant social and economic losses for the health care system and society.Aim. To predict the socio-economic burden of COPD in the Russian Federation in 2022, including the cost of drug treatment.Methods. The socio-economic burden of COPD in the Russian Federation in 2022 was predicted with and without taking into account the impact of COVID-19. The analysis of the cost of illness included the calculation of direct and indirect costs due to COPD. Data of Federal State Statistics Service, the State Guarantee Program of Free Medical Care for Citizens of Russian Federation, and data from the regional register of drug treatment of patients with COPD were used. Costs of medical care (ambulatory, hospital, and emergency care) were calculated based on compulsory health insurance tariffs. The disability benefits payments were calculated based on number of disabled persons and the amount of the disability benefit in each group. Indirect costs (or economic losses) included losses from products which were not produced due to disability and premature mortality of working-aged adults.Results. The predicted total economic losses due to COPD in 2022 will be 428.5 billion rubles when taking into account the impact of COVID-19, and 378.9 billion rubles when not accounting for COVID-19. Losses in the economy due to decreased labor productivity because of premature deaths (86%) are major part of the main burden. The cost of drug therapy for patients with COPD in outpatient settings will amount to over 17 billion rubles.Conclusion. Potential economic burden of COPD in 2022 depends on the incidence of COVID-19 and could be 0.34% of the GDP. Priority should be given to measures aimed at preventing the occurrence of COPD by correcting risk factors in the population, early diagnosis, slowing the progression of the disease and preventing exacerbations. Prevention of respiratory infections including COVID-19 in patients with COPD plays a special role.

1 January 2019 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
PDF file
AKA. V. Kontsevaya
A. V. Kontsevaya
AMA. A. Myrzamatova
A. A. Myrzamatova
DMD. K. Mukaneeva
D. K. Mukaneeva
ISI. D. Sapunova
I. D. Sapunova
YBYulia Balanova
Yulia Balanova
ADA. M. Drapkina
A. M. Drapkina

4 March 2020 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AKA. V. Kontsevaya
A. V. Kontsevaya
DMD. K. Mukaneeva
D. K. Mukaneeva
AMA. O. Myrzamatova
A. O. Myrzamatova
YBYulia Balanova
Yulia Balanova
MKM. B. Khudyakov
M. B. Khudyakov
ODOxana M. Drapkina
Oxana M. Drapkina
Aim.To assess the socioeconomic damage of risk factors associated with morbidity and mortality from major chronic non-communicable diseases (CNCDs) in the Russian population in 2016.Material and methods.The following RF were included in the analysis: smoking, alcohol abuse, high salt intake, insufficient consumption of vegetables and fruits, consumption of processed red meat, low physical activity, obesity, hypertension (HTN), which have a significant causal relationship with the major CNCDs: cardiovascular diseases (CVDs), type 2 diabetes, chronic obstructive pulmonary disease (COPD), cancer of 10 locations (lung, breast, cervix, ovary, prostate, kidney, stomach, liver, pancreas, colon). Based on the data on the RF prevalence in the Russian population by ESSE-RF study and relative risks by large studies, the population attributable risk for each CNCD was estimated. We used the data of the Federal State Statistics Service, annual forms of Federal Statistical Observation, as well as the results of the Government Guarantee Program for free medical care and the corresponding diagnosis-related groups for 2016. The direct costs of the healthcare system and economic losses due to morbidity and mortality from the major CNCDs associated with the considered RF are determined. The calculations were performed in Microsoft Excel 10.0.Results.Indirect losses due to premature mortality prevail over direct costs of medical care and disability benefits in the economic damage structure of each RF. The largest damage of four major CNCDs was associated with HTN — 869,9 billion rubles, which is equivalent to 1,01% of gross domestic product (GDP). The next places were taken by obesity — 605,8 billion rubles (0,7% of GDP), smoking — 421,4 billion rubles (0,49% of GDP) and low physical activity — 273,0 billion rubles. (0,32% of GDP). The contribution of improper feeding (high salt intake, insufficient consumption of vegetables and fruits, consumption of processed red meat) amounted to 0,17% of GDP (145,3 billion rubles), 0,19% of GDP (160,9 billion rubles) and 0,10% of GDP (83,4 billion rubles), respectively. Alcohol abuse made the smallest contribution to CNCD-related damage — 82,5 billion rubles (0.1% of GDP). This is due to the low prevalence of alcohol abuse in the Russian population according to ESSE-RF study.Conclusion.Assessment of the economic damage of CNCD RF allows determining the priority areas in healthcare and substantiating the effectiveness of CNCD preventive measures aimed at reducing the RF impact, and, consequently, the burden on the healthcare system and the national economy.

16 July 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AKA. V. Kontsevaya
A. V. Kontsevaya
DMD. K. Mukaneeva
D. K. Mukaneeva
VIV. I. Ignatieva
V. I. Ignatieva
AAA. A. Antsiferova
A. A. Antsiferova
ODOxana M. Drapkina
Oxana M. Drapkina
Cardiovascular diseases (CVDs) are the leading threat to the population health in the Russian Federation (RF), ranking first in the mortality structure. Demonstration of the economic impact of CVD is a rationale for investing in prevention and treatment. The economic damage caused by CVD in 2016 in the RF amounted to RUB 2,7 trillion, which is equivalent to 3,2% of gross domestic product (GDP). In the structure of damage by diseases, coronary artery disease occupies a leading position — RUB 1 trillion or 1,3% of GDP, while cerebrovascular diseases, stroke and myocardial infarction — RUB 560, 424 and 213,2 billion, respectively. Evaluation of cardiovascular prevention measures is not an easy task because the effect develops over a significant period of time. At the same time, various processes can affect the effect. The RF analysis showed that the potential economic effect from anti-tobacco and anti-alcohol measures, reducing salt consumption and increasing physical activity will be RUB 8,1 trillion in labor productivity increase over 15 years (equivalent to 7,8% of GDP in 2018), with most of the effect from the prevention of CVD deaths. Analyzing the economic impact of CVDs, preventive and curative measures provide a rationale for investment and is an important step in making informed decisions.

4 March 2020 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AKA. V. Kontsevaya
A. V. Kontsevaya
DMD. K. Mukaneeva
D. K. Mukaneeva
AMA. O. Myrzamatova
A. O. Myrzamatova
YBYu. A. Balanova
Yu. A. Balanova
MKM. B. Khudyakov
M. B. Khudyakov
ODO. M. Drapkina
O. M. Drapkina
Экономический ущерб факторов риска, обусловленный их вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации в 2016 году